Suggestions
Kåre Engkilde
Chief Executive Officer & Life Science Executive
Kåre Engkilde is the Chief Executive Officer of Amniotics AB, a Swedish biotech company specializing in stem cell therapies. He holds a PhD in Immunology and has a robust background in the life sciences sector, particularly in medtech, diagnostics, and therapeutics.
Professional Background
Engkilde has been instrumental in the growth of Amniotics AB, successfully bootstrapping the startup and leading it through an initial public offering (IPO). Under his leadership, the company's valuation increased more than fourfold within four years. He has also played a critical role in advancing innovative therapies from early clinical stages to successful market launches.12
His previous experience includes significant roles at various prominent organizations such as Bioneer, LEO Pharma, and Novo Nordisk. Engkilde's expertise encompasses strategic planning, business development, fundraising, and regulatory affairs, making him a well-rounded leader in the biotech industry.12
Achievements
- Successful IPO: Led Amniotics through its IPO, significantly increasing the company's market value.
- Global Market Expansion: Successfully accelerated the development of a pioneering product to global markets within three years.
- Research Contributions: Co-authored studies on stem cell treatments for conditions like chemotherapy-induced peripheral neuropathy.3
Skills and Strengths
Engkilde is known for his strategic vision and authentic leadership style. He emphasizes fostering a culture of innovation and collaboration within his teams. His ability to navigate complex regulatory environments and develop strategic partnerships is a hallmark of his career.12
Languages
He is proficient in multiple languages including Danish (native), English (full professional), and has limited working proficiency in Norwegian and Swedish.1
Kåre Engkilde's extensive experience and leadership in biotechnology position him as a key figure in advancing regenerative medicine and innovative therapeutic solutions.